AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
  3. Financials
  4. Long-term debt, current

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.【JP:2395】

Market cap
¥64.4B
P/E ratio
18.1x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndLong-term debt, current (Million JPY)YoY (%)
Mar 31, 20258,665+14.01%
Mar 31, 20247,600+58.66%
Mar 31, 20234,790+71.07%
Mar 31, 20222,800-16.80%
Mar 31, 20213,365-13.10%
Mar 31, 20203,872+17.08%
Mar 31, 20193,307-25.99%
Mar 31, 20184,469-19.90%
Mar 31, 20175,579-5.21%
Mar 31, 20165,886-2.02%
Mar 31, 20156,007

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)